Rachael M. Bushey

• Represented a biotechnology company utilizing a comprehensive cell therapy platform to develop allogeneic cell therapies in its $242.7 million initial public offering*
• Represented a clinical-stage biopharmaceutical company in its $45.2 million initial public offering*
• Represented a commercial-stage biotechnology company developing surgical reconstruction products in its $60 million initial public offering*
• Represented a syndicate of underwriters led by SVB Leerink in connection with a clinical-stage biopharmaceutical company’s public offering of common stock*
• Represented SVB Leerink and the syndicate of underwriters in ATM work for a clinical-stage biopharmaceutical company*
• Represented a syndicate of placement agents in its $30 million registered direct offering of a pharmaceutical logistics company*
• Represented a specialty pharmaceutical company in its $35 million follow-on public offering*
• Represented a commercial-stage device company in connection with its initial public offering of common stock through a syndicate of underwriters*
• Represented a pre-clinical company in connection with its initial public offering of common stock through a syndicate of underwriters*
• Represented a clinical-stage pharmaceutical company in connection with its initial public offering of common stock through a syndicate of underwriters led by Leerink and Cowen*
• Represented a medical device company in connection with its tender offer to purchase $161.5 million of convertible junior subordinated debentures led by Banc of America Securities and Wachovia Securities*
• Represented a pharmaceutical packaging company in connection with its $168 million private placement of unsecured notes*
• Represented a biotech company in connection with its $50 million CMPO*
• Represented a specialty pharmaceutical company in connection with its $50 million follow-on offering*
• Represented a specialty pharmaceutical company in connection with its registration of privately placed securities*

*Denotes experience prior to joining Goodwin.

• Represented a global health care leader in drug development in its recent acquisition of a privately held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration*
• Represented an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, in a reverse merger with a special purpose acquisition company, for a total deal value of $95.1 million*
• Represented a clinical stage biopharmaceutical company developing immune-modulating therapies targeting cancer, ARS, inflammatory and autoimmune diseases, and viruses, including COVID-19, in its reverse merger with a clinical-stage biotechnology company focused on oncology development*
• Represented a contract development and manufacturing organization (CDMO), in its acquisition of a San Diego-based CDMO, for a combination of stock, cash, and promissory notes*
• Represented a biotech company in its acquisition of product assets (including a license and supply agreement for certain technologies) and a contract manufacturing business from a global pharmaceutical company*
• Represented a contract sales and diagnostic company in the divestiture of its contract sales business*
• Represented a publicly traded international generic pharmaceutical company in the potential acquisition of a generic pharmaceutical company*
• Represented a medical device company in connection with its equity investment in a digital health company*
• Represented a private drug company in its acquisition of certain products assets from a publicly traded drug company and subsequent license for technologies*
• Represented a leading publicly traded packaging and drug delivery device company in connection with the acquisition of a wearable patch injector*
• Represented a public packaging and device company in connection with its acquisition of product assets and intellectual property for needle safety shield technologies*
• Represented a diagnostic company in its divestiture of diagnostic assets and a manufacturing facility*

*Denotes experience prior to joining Goodwin.